Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
120.00
Ask:
200.00
Spread: 80.00 (66.667%)
Market Cap: £77.39m
SPSC Live PriceLast checked at - London Stock Exchange

Intraday Spectra (di/ S) Share Chart

Second G8 Central Bank Test Program

13 Jan 2014 07:00

RNS Number : 4338X
Spectra Systems Corporation
13 January 2014
 



Spectra Systems Corporation ("Spectra Systems" or the "Company")

 

Second G 8 central bank test program for supercritical fluid cleaning of banknotes

 

The Board is delighted to announce that Spectra Systems has agreed to enter into a testing program scheduled to begin in April of this year, with a second G 8 central bank to evaluate its supercritical CO2 ("SCCO2") technology involving the use of supercritical fluids to clean heavily soiled banknotes, thereby allowing them to be returned to circulation and effectively increasing their life. This follows the ongoing trial with the first G8 central bank announced on 25 November 2013.

With banknote replacement costs approaching $10 billion annually, and most banknotes being replaced due to soiling, data from these central bank testing programs will be invaluable to the Company for determining the potential of this technology for creating a sizable revenue steam if adopted by major central banks. Spectra Systems will provide data to the industry from these trials at the Banknote 2014 conference in Washington DC commencing on 7 April 2014.

Spectra Systems also announces that its seminal work on the cleaning of soiled banknotes using SCCO2 has been published in the prestigious peer reviewed journal of the American Chemical Society, Industrial and Chemical Engineering Research. The paper, entitled "Supercritical Fluid Cleaning of Banknotes", is authored by Nabil M. Lawandy and Andrei Y. Smuk, Spectra's CEO and Director of Research and Development, respectively. The American Chemical Society has chosen to highlight this work in a featured press release http://www.acs.org/content/acs/en/pressroom.html) which has received broad coverage, including the Los Angeles Times (http://touch.latimes.com/#section/-1/article/p2p-78822882/) and other international news bureaus (see News section on the Company website: http://www.spectra-science.com/company-news.html)

 

Nabil Lawandy, Spectra System's CEO, stated:

"Spectra Systems is founded on cutting edge technology and the publication of our work in a leading scientific journal provides third party validation for its breakthrough technical results. The addition of a second G 8 central bank to the testing program will provide more data to help us formulate a compelling business proposition to the industry"

Enquiries:

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer Tel: +1 (0) 401 274 4700

WH Ireland Limited

Chris Fielding (Head of Corporate Finance) Tel: +44 (0) 20 7220 1650

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBMMFTMBIBBBI
Date   Source Headline
22nd May 20262:45 pmRNSAdditional Sensor order
16th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
8th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
30th Mar 20267:00 amRNSAudited results for year ended 31 December 2025
5th Feb 20267:00 amRNSExecuted Contract with HMRC for Vaping Duty Stamps
16th Jan 20267:00 amRNSSuccessful Bid for HMRC Vaping Duty Stamps Scheme
8th Dec 20257:00 amRNSTransaction in Own Shares & TVR
26th Nov 20257:01 amRNSTransaction in Own Shares & TVR
26th Nov 20257:00 amRNSMaintenance contract for new sensors
25th Nov 20257:00 amRNSShare Buyback Programme
16th Oct 20257:00 amRNSAppointment of Finance Director
29th Sep 20257:00 amRNSInterim Results for Six Months Ended 30 June 2025
9th Sep 20252:59 pmRNSNotice of Interim Results
27th Jun 20257:00 amRNSExercise of Options
24th Jun 20254:48 pmRNSAnnual General Meeting Lack of Quorum
11th Jun 20257:00 amRNSNotice of AGM
27th May 20255:33 pmRNSAppointment of Finance Director
9th Apr 20254:55 pmRNSHolding(s) in Company
7th Apr 20257:00 amRNSExercise of Options & Removal of Reg S
31st Mar 20257:00 amRNSAudited results for year ended 31 December 2024
9th Jan 20257:00 amRNSExercise of Options
18th Dec 20243:58 pmRNSExercise of Options
18th Dec 20247:00 amRNS$9.4M downpayment on sensor manufacturing contract
21st Oct 20244:00 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
20th Aug 20244:35 pmRNSRemoval of Reg S restrictions from common stock
30th Jul 20247:00 amRNSAnnual General Meeting Lack of Quorum
18th Jul 20244:52 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNew $37.9 million sensor manufacturing contract
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
28th Jun 20241:46 pmRNSReplacement: Posting of Annual Report
28th Jun 202410:14 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSIssue of Equity & Update to Dividend Timetable
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.